1211441-98-3 | 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$52.00	$36.00
10mg	95%	in stock	$88.00	$62.00
25mg	95%	in stock	$116.00	$81.00
1g	95%	in stock	$139.00	$97.00
5g	95%	in stock	$387.00	$271.00
10g	95%	in stock	$667.00	$467.00
25g	95%	in stock	$1,319.00	$923.00

Description

• Catalog Number: AB53164
• Chemical Name: 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
• CAS Number: 1211441-98-3
• Molecular Formula: C23H30N8O
• Molecular Weight: 434.5373
• MDL Number: MFCD27976795
• SMILES: CN(C(=O)c1cc2c(n1C1CCCC1)nc(nc2)Nc1ccc(cn1)N1CCNCC1)C

Computed Properties

• Complexity: 636
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• XLogP3: 2.2

Upstream Synthesis Route

7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is a versatile compound widely utilized in chemical synthesis processes. Its unique molecular structure allows for strategic incorporation into various synthetic routes for the production of pharmaceuticals, agrochemicals, and specialty chemicals. This compound serves as a valuable building block in the construction of complex heterocyclic compounds, enabling the synthesis of novel drug candidates and functional materials through diverse chemical transformations. Its presence in the design of synthetic pathways contributes to the efficient assembly of diverse molecular architectures with high precision and yield, making it an indispensable tool for synthetic chemists working in medicinal chemistry, material science, and chemical synthesis research.

Literature

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

  The Lancet. Oncology 20180701

• A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20161201

• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  The New England journal of medicine 20161103

• Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20131115

• A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.

  Cancer biology & therapy 20130701

• The requirement for cyclin D function in tumor maintenance.

  Cancer cell 20121016

• Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

  Cancer cell 20121016

• Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

  Cell cycle (Georgetown, Tex.) 20120715

• Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.

  Biochimica et biophysica acta 20110801

• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  Cancer cell 20100713

• The landscape of somatic copy-number alteration across human cancers.

  Nature 20100218

• Requirement for CDK4 kinase function in breast cancer.

  Cancer cell 20060101